| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02296476 | Glioblastoma Multiforme | Drug: OTX015 | Oncoethix GmbH | Phase 1|Phase 2 | 2014-10-01 | 2016-08-10 |
| NCT01713582 | Acute Myeloid Leukemia|Diffuse Large B-cell Lymphoma|Acute Lymphoblastic Leukemia|Multiple Myeloma | Drug: OTX015/MK-8628 | Oncoethix GmbH | Phase 1 | 2012-12-01 | 2017-02-23 |
| NCT02303782 | Acute Myeloid Leukemia | Drug: OTX015|Drug: Vidaza (azacitidine) | Oncoethix GmbH | Phase 1|Phase 2 | 2015-01-01 | 2016-08-31 |
| NCT02259114 | NUT Midline Carcinoma|Triple Negative Breast Cancer|Non-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation|Castrate-resistant Prostate Cancer (CRPC)|Pancreatic Ductal Adenocarcinoma | Drug: OTX015/MK-8628 | Oncoethix GmbH | Phase 1 | 2014-10-01 | 2017-01-20 |
| NCT02698176 | NUT Midline Carcinoma (NMC)|Triple Negative Breast Cancer (TNBC)|Non-small Cell Lung Cancer (NSCLC)|Castration-resistant Prostate Cancer (CRPC) | Drug: MK-8628 Dose 1|Drug: MK-8628 Dose 2|Drug: MK-8628 Dose 3|Drug: MK-8628 NMC Cohort Dose | Merck Sharp & Dohme Corp. | Phase 1 | 2016-05-01 | 2017-03-17 |
| NCT02698189 | AML Including AML de Novo and AML Secondary to MDS|DLBCL | Drug: MK-8628 Dose A|Drug: MK-8628 Dose B | Merck Sharp & Dohme Corp. | Phase 1 | 2016-05-01 | 2017-03-17 |
